Search research articles
Contact Us
Filters
Showing results (511-520 of 524) with videos related to
Page
of 53
Sort By:
Journal of the American Heart Association
|
April 30, 2024
Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study
Brittany Weber, Dana Weisenfeld, Elena Massarotti, et al.
Pain Medicine (Malden, Mass.)
|
August 13, 2011
Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them
M Cary Reid, David A Bennett, Wen G Chen, et al.
American Journal of Ophthalmology
|
September 13, 2012
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study
Kevin L Winthrop, Lang Chen, Frederick W Fraunfelder, et al.
ACR Open Rheumatology
|
March 24, 2025
The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid Symptoms
Daniel H Solomon, Misti Paudel, Shravani Chitineni, et al.
JAMA
|
May 4, 2021
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, et al.
The Lancet. Rheumatology
|
April 7, 2024
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
Kaja E Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, et al.
The New England Journal of Medicine
|
November 13, 2018
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M Ridker, Brendan M Everett, Aruna Pradhan, et al.
Contemporary Clinical Trials
|
July 17, 2012
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States
Kenneth G Saag, Penny E Mohr, Laura Esmail, et al.
Annals of Internal Medicine
|
February 18, 2020
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial
Daniel H Solomon, Robert J Glynn, Elizabeth W Karlson, et al.
Biomed Research International
|
April 3, 2015
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy
Helena Canhão, Ana Maria Rodrigues, Maria José Santos, et al.
Page
of 53
Search research articles
Search
Showing results (511-520 of 524) with videos related to
Sort By:
Page
of 53
Journal of the American Heart Association
|
April 30, 2024
Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study
Brittany Weber, Dana Weisenfeld, Elena Massarotti, et al.
Pain Medicine (Malden, Mass.)
|
August 13, 2011
Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them
M Cary Reid, David A Bennett, Wen G Chen, et al.
American Journal of Ophthalmology
|
September 13, 2012
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study
Kevin L Winthrop, Lang Chen, Frederick W Fraunfelder, et al.
ACR Open Rheumatology
|
March 24, 2025
The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid Symptoms
Daniel H Solomon, Misti Paudel, Shravani Chitineni, et al.
JAMA
|
May 4, 2021
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, et al.
The Lancet. Rheumatology
|
April 7, 2024
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
Kaja E Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, et al.
The New England Journal of Medicine
|
November 13, 2018
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M Ridker, Brendan M Everett, Aruna Pradhan, et al.
Contemporary Clinical Trials
|
July 17, 2012
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States
Kenneth G Saag, Penny E Mohr, Laura Esmail, et al.
Annals of Internal Medicine
|
February 18, 2020
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial
Daniel H Solomon, Robert J Glynn, Elizabeth W Karlson, et al.
Biomed Research International
|
April 3, 2015
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy
Helena Canhão, Ana Maria Rodrigues, Maria José Santos, et al.
Page
of 53